Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

106

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

October 31, 2029

Conditions

Locally Advanced Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

Pucotenlimab

200mg every 3 weeks (21-day cycles) for a total of 3 cycles.

DRUG

MRG003

2.3 mg/kg, every 3 weeks (21-day cycles) for a total of 3 cycles.

All Listed Sponsors

collaborator

Lepu Medical Technology (Beijing) Co., Ltd.

INDUSTRY

lead

Groupe Oncologie Radiotherapie Tete et Cou

OTHER